财务数据和关键指标变化 - 公司在第一季度录得总收入9400万美元,较上年同期增加 [57] - 公司大幅降低了第一季度的研发和销售费用,同比下降50% [57] - 公司在第一季度末拥有5.7亿美元的现金和应收账款 [58] - 公司预计2024年全年总收入将在4亿至6亿美元之间,较之前预期有所下降 [65] - 公司计划在2025年将研发和销售费用控制在5亿美元以下,其中部分费用将由赛诺菲承担 [120] 各条业务线数据和关键指标变化 - 公司在第一季度的产品销售收入为8200万美元,主要来自欧洲APA交付 [59] - 公司正在与澳大利亚、新西兰和以色列等国家就APA合同进行调整,以更好地满足当前的市场需求 [65] 各个市场数据和关键指标变化 - 公司在美国市场计划采取更具竞争力的单剂量预填充注射器,并计划在8月中旬前将产品送到分销中心 [29][30] - 公司在欧洲市场正式进入商业销售阶段,并正在与主要国家进行合作 [34] - 公司在加拿大、澳大利亚、新西兰和以色列等APA市场正在与客户进行合同调整,以更好地满足当前需求 [65] 公司战略和发展方向及行业竞争 - 公司与赛诺菲达成全球合作开发和共同销售协议,这是一个具有多亿美元潜力的交易 [9][10][11] - 该协议使公司能够转向一种更精简的运营模式,专注于研发和管线拓展,以加速增长并为股东创造长期价值 [12][15] - 公司将保留自主开发的CIC和独立流感疫苗的能力,并考虑增加一些新的早期项目 [15][16] - 公司计划利用矩阵-M佐剂技术与赛诺菲合作开发新疫苗,并从中获得可观的特许权使用费和里程碑付款 [13][20][21] - 公司认为这笔交易进一步验证了其产品开发能力和矩阵-M佐剂技术的价值,将增强未来的许可和业务发展机会 [17] 管理层对经营环境和未来前景的评论 - 公司管理层表示,过去15个月来一直在努力实现三大战略重点,为达成重大业务发展机会做好准备 [23] - 公司将在2024年剩余时间内重点关注:1)与赛诺菲的合作顺利过渡;2)拓展和多元化自主机会;3)实施进一步的成本削减计划;4)交付2024-2025年度更新的疫苗产品 [24] - 公司表示未来几个月内将分析和明确未来管线和战略重点,并计划在今年年底前与投资者分享更新的计划 [24] 问答环节重要的提问和回答 问题1 **Roger Song 提问** 询问赛诺菲合作中的成本报销情况,以及公司未来的盈亏平衡预期 [71][72][73][120] **John Jacobs 和 James Kelly 回答** - 赛诺菲将承担一些研发活动和技术转移等方面的费用,预计2025年这部分费用可达1亿美元左右 - 公司目标是实现现金流正转和价值创造,相信与赛诺菲的合作将带来优于自营的现金流 - 公司将继续提供业务模式演变方面的更新信息 问题2 **Mayank Mamtani 提问** 询问BLA提交进度以及非APA收入中的市场份额假设 [108][109][110][113][114] **John Trizzino 回答** - 公司正在同FDA沟通,选择先通过EUA途径更新疫苗,以确保及时上市 - 公司有信心在2024-2025季度大幅提升在美国市场的表现,主要得益于新的剂型和及时上市 问题3 **Brendan Smith 提问** 询问是否考虑FDA可能提前批准更新加强针,以及公司在非COVID/流感领域的战略规划 [125][126][127] **John Jacobs 和 Filip Dubovsky 回答** - 公司一直与监管机构保持密切沟通,并做好各种情况的准备 - 公司未来几个月将进一步明确自主管线和增长战略,并计划与投资者分享更多细节 - 公司已展示了一些新技术和早期项目,未来将考虑如何优化这些资产

A cloud of doubt hanging over the company just gave way to some sunshine.Shares of Novavax (NVAX 96.20%) are up 12% as of midday Friday following the release of the drugmaker's first-quarter results. It's not the report, however, driving the bulk of today's oversize gain -- it's the announcement made in conjunction with it.The company is partnering with fellow pharmaceutical company Sanofi (SNY 0.90%) to market Novavax's COVID vaccine. The deal also opens the door to the development of a flu vaccine based o ...

Novavax (NASDAQ:NVAX) stock investors are celebrating on Friday as the vaccine company’s shares hit a new 52-week high after announcing a deal with Sanofi (NASDAQ:SNY).This saw shares of NVAX stock climb as high as $9.22 per share during normal trading hours on Friday. That comes with some 142 million shares of the stock changing hands. For the record, this is well above its daily average of about 6.8 million shares.Investors will note that NVAX stock hasn’t been in this range since September 2022. However, ...

Novavax (NASDAQ:NVAX) stock has more than doubled today and is up more than 120% at the time of this writing. This morning, the company announced a co-exclusive licensing agreement with Sanofi (NASDAQ:SNY) to commercialize its Covid-19 vaccine. The agreement will also provide Sanofi with a sole license to the vaccine for use in combination with its flu vaccines.On top of that, Sanofi will receive “a non-exclusive license to use Novavax’s adjuvanted COVID-19 vaccine for use in combination with non-flu vaccin ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Key TakeawaysNovavax shares more than doubled in intraday trading Friday as it announced a $1.2 billion deal to license its vaccine technology to Sanofi.Novavax will co-commercialize its COVID-19 vaccine with the French drugmaker, along with developing others like a combination COVID-19 and flu vaccine.The vaccine maker also announced first-quarter results that included a wider-than-expected net loss. Novavax (NVAX) shares more than doubled in intraday trading Friday after announcing a $1.2 billion deal to ...

Forbes Community GuidelinesOur community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space.In order to do so, please follow the posting rules in our site's Terms of Service.  We've summarized some of those key rules below. Simply put, keep it civil.Your post will be rejected if we notice that it seems to contain:False or intentionally out-of-context or misleading informationSpamInsults, profanity, incoh ...

Exhibit 99.1 Press Release Novavax Reports First Quarter 2024 Financial Results and Operational Highlights · Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19- Influenza combination vaccines and develop multiple new vaccines utilizing Novavax’s Matrix-M adjuvant · This agreement represents a potential multi-billion dollar revenue opportunity for Novavax including: o $500 million upfront payment o Approximately $70 million equity investment in ...

Novavax (NVAX) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $3.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -0.96%. A quarter ago, it was expected that this vaccine maker would post a loss of $0.49 per share when it actually produced a loss of $1.44, delivering a surprise of -193.88%.Over the last four quarters, the company has surpasse ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 000-26770 NOVAVAX, INC. (Exact name of registrant as specified in its charter) Delaware 22-2816046 (State or other jurisdictio ...